Industry

BOSTON–(BUSINESS WIRE)–#accelerator–The Japan External Trade Organization (JETRO) and CIC Japan Desk will once again host “Japan Innovation Night: Best in Biotech” – a groundbreaking event showcasing the latest advancements in biotechnology from Japanese startups. This exclusive gathering will take place on Wednesday, June 18th, 2025, from 5:30pm to 8pm in Venture Café at CIC Cambridge. … [Read more…]

NEW YORK–(BUSINESS WIRE)–Tracer Biotechnologies, a leader in blood-based molecular diagnostics for cancer, is pleased to announce a strategic partnership with QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) to co-develop and commercialize minimal residual disease (MRD) assays for solid tumors on QIAGEN’s QIAcuity digital PCR platform. This collaboration aims to deliver highly sensitive, cost-effective, and decentralized … [Read more…]

—GlycoMimetics Board of Directors approves 1-for-100 reverse stock split— ROCKVILLE, Md.–(BUSINESS WIRE)–GlycoMimetics, Inc. (Nasdaq: GLYC) (“GlycoMimetics”) today announced that its stockholders have approved the proposed merger (the “Merger”) with Crescent Biopharma, Inc. (“Crescent”), along with all proposals related to the Merger. The proposals were voted upon at GlycoMimetics’ special meeting in lieu of the annual … [Read more…]

SWEDESBORO, N.J.–(BUSINESS WIRE)–#AnimalHealth–Wedgewood Pharmacy today announced the availability of a GS-441524 formula, a compounded oral antiviral formulation now part of its feline infectious peritonitis (FIP) treatment capabilities. With this addition, veterinarians can now prescribe both GS-441524 and Molnupiravir for their patients, two of the most requested compounded antivirals for FIP, through a single trusted source … [Read more…]

Exclusive-Licensing Partner Santen Will Commercialize SYD-101 Under the Brand Name Ryjunea® in the European Union DEL MAR, Calif.–(BUSINESS WIRE)–Sydnexis, Inc., (www.sydnexis.com) a pre-commercial stage biopharmaceutical company today announced that the European Commission (EC) has granted marketing authorization for SYD-101, the company’s proprietary low-dose atropine formulation, for slowing the progression of pediatric myopia. As the first … [Read more…]

CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of six scientific abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 taking place in Glasgow, United Kingdom from June 13–16, 2025. Details are as follows: Friday, June 13 Potential for Sebetralstat to Address Pseudo-allergic Reaction Burden … [Read more…]

TOKYO & SUNNYVALE, Calif.–(BUSINESS WIRE)–#IVD–Fujirebio, a leading innovator in in-vitro diagnostics, today announced a collaboration with Stanford Medicine (Location: Palo Alto, California, USA) to advance research and innovation in the field of infectious disease testing. This collaboration aims to accelerate the adoption of ultrasensitive immunoassays that incorporate single-molecule counting technology developed by Fujirebio’s Silicon Valley … [Read more…]

BANGALORE, India–(BUSINESS WIRE)–The Eurofins Consumer Product Testing network of laboratories in India recently unveiled its expanded, state-of-the-art facilities in Hongasandra, Bangalore. This strategic investment doubles the Bangalore laboratory’s footprint and offers enhanced capabilities, enabling a significant leap in compliance and performance testing tailored to the evolving needs of India’s textile, apparel, footwear, and leather goods … [Read more…]

SHANGHAI & INDIANAPOLIS–(BUSINESS WIRE)–Acerand Therapeutics, a clinical-stage biotech company focusing on the discovery and development of innovative small-molecule therapies in oncology, today announced the dosing of the first patient in its first-in-human Phase I clinical trial (NCT06801236) of ACE-232, a novel oral inhibitor of CYP11A1. The trial is being conducted in patients with metastatic castration-resistant … [Read more…]

BEIJING & NANJING, China–(BUSINESS WIRE)–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (“NJCTTQ”) announced that NTB003 (formerly BCG009), a co-developed injectable drug candidate, has received the Investigational New Drug (IND) approval from the National Medical Products Administration (NMPA). The approved indication is Thyroid Eye Disease (TED). About … [Read more…]